Literature DB >> 23850949

Diagnostic implications of inconsistent results obtained with the Xpert MTB/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance.

Akos Somoskovi1, Vanessa Deggim, Diana Ciardo, Guido V Bloemberg.   

Abstract

Xpert-MTB/Rif is one of the most frequently used molecular screening tests for multidrug-resistant tuberculosis worldwide. We report false-negative assay results in the presence of rpoB Leu533Pro, which is associated with low-level phenotypic rifampin resistance. Accurate and timely confirmation of rifampin susceptibility results obtained with Xpert-MTB/Rif is imperative.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23850949      PMCID： PMC3754655          DOI： 10.1128/JCM.01377-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  14 in total

1.  Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs.

Authors:  E V Kurbatova; J S Cavanaugh; N S Shah; A Wright; H Kim; B Metchock; A Van Deun; L Barrera; F Boulahbal; E Richter; N Martín-Casabona; F Arias; I Zemanova; F Drobniewski; A Santos Silva; C Coulter; R Lumb; J P Cegielski
Journal:  Int J Tuberc Lung Dis       Date:  2012       Impact factor: 2.373

2.  Evaluation of the analytical performance of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Elizabeth Story; Danica Helb; JoAnn Kop; Padmapriya Banada; Michelle R Owens; Soumitesh Chakravorty; Martin Jones; David Alland
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

3.  Rifampin drug resistance tests for tuberculosis: challenging the gold standard.

Authors:  Armand Van Deun; Kya J M Aung; Valentin Bola; Rossin Lebeke; Mohamed Anwar Hossain; Willem Bram de Rijk; Leen Rigouts; Aysel Gumusboga; Gabriela Torrea; Bouke C de Jong
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

4.  Rapid molecular detection of tuberculosis.

Authors:  Andrea Zbinden; Peter M Keller; Guido V Bloemberg
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

Review 5.  Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF.

Authors:  Karin Weyer; Fuad Mirzayev; Giovanni Battista Migliori; Wayne Van Gemert; Lia D'Ambrosio; Matteo Zignol; Katherine Floyd; Rosella Centis; Daniela M Cirillo; Enrico Tortoli; Chris Gilpin; Jean de Dieu Iragena; Dennis Falzon; Mario Raviglione
Journal:  Eur Respir J       Date:  2012-11-22       Impact factor: 16.671

Review 6.  Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs.

Authors:  David J Horne; Lancelot M Pinto; Matthew Arentz; S-Y Grace Lin; Edward Desmond; Laura L Flores; Karen R Steingart; Jessica Minion
Journal:  J Clin Microbiol       Date:  2012-11-14       Impact factor: 5.948

7.  An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis.

Authors:  Deborah A Williamson; Indira Basu; James Bower; Joshua T Freeman; Gillian Henderson; Sally A Roberts
Journal:  Diagn Microbiol Infect Dis       Date:  2012-07-20       Impact factor: 2.803

8.  Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis.

Authors:  D A Williamson; S A Roberts; J E Bower; R Vaughan; S Newton; O Lowe; C A Lewis; J T Freeman
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

9.  Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.

Authors:  F K Mukinda; D Theron; G D van der Spuy; K R Jacobson; M Roscher; E M Streicher; A Musekiwa; G J Coetzee; T C Victor; B J Marais; J B Nachega; R M Warren; H S Schaaf
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

10.  Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.

Authors:  Lesley E Scott; Kerrigan McCarthy; Natasha Gous; Matilda Nduna; Annelies Van Rie; Ian Sanne; Willem F Venter; Adrian Duse; Wendy Stevens
Journal:  PLoS Med       Date:  2011-07-26       Impact factor: 11.069
View more
  17 in total

1.  False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load.

Authors:  Oksana Ocheretina; Erin Byrt; Marie-Marcelle Mabou; Gertrude Royal-Mardi; Yves-Mary Merveille; Vanessa Rouzier; Daniel W Fitzgerald; Jean W Pape
Journal:  Diagn Microbiol Infect Dis       Date:  2016-01-15       Impact factor: 2.803

2.  Evaluation of the AID TB resistance line probe assay for rapid detection of genetic alterations associated with drug resistance in Mycobacterium tuberculosis strains.

Authors:  C Ritter; K Lucke; F A Sirgel; R W Warren; P D van Helden; E C Böttger; G V Bloemberg
Journal:  J Clin Microbiol       Date:  2014-01-08       Impact factor: 5.948

3.  Described diagnostic inconsistencies were observed with an obsolete version of the Xpert MTB/RIF assay and are unlikely to recur in the current version of the assay.

Authors:  Robert Blakemore; David Alland
Journal:  J Clin Microbiol       Date:  2014-02       Impact factor: 5.948

4.  Reply to "described diagnostic inconsistencies were observed with an obsolete version of the Xpert MTB/RIF assay and are unlikely to recur in the current version of the assay".

Authors:  Akos Somoskovi; Guido V Bloemberg
Journal:  J Clin Microbiol       Date:  2014-02       Impact factor: 5.948

5.  Reply to "performance of the Xpert MTB/RIF assay on nonrespiratory specimens and accuracy of this assay for detection of rifampin resistance in a low-prevalence setting".

Authors:  Vanessa Deggim; Akos Somoskovi; Guido Bloemberg
Journal:  J Clin Microbiol       Date:  2014-02       Impact factor: 5.948

6.  Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis.

Authors:  Syed Beenish Rufai; Parveen Kumar; Amit Singh; Suneel Prajapati; Veena Balooni; Sarman Singh
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

7.  Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.

Authors:  Gustavo E Velásquez; Roger I Calderon; Carole D Mitnick; Mercedes C Becerra; Chuan-Chin Huang; Zibiao Zhang; Carmen C Contreras; Rosa M Yataco; Jerome T Galea; Leonid W Lecca; Megan B Murray
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests.

Authors:  Nicola M Zetola; Chawangwa Modongo; Patrick K Moonan; Ronald Ncube; Keikantse Matlhagela; Enoch Sepako; Ronald G Collman; Gregory P Bisson
Journal:  J Infect Dis       Date:  2014-01-16       Impact factor: 5.226

9.  Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.

Authors:  Sang-Won Park; Rokeya Tasneen; Paul J Converse; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

10.  Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis.

Authors:  Paolo Miotto; Andrea M Cabibbe; Emanuele Borroni; Massimo Degano; Daniela M Cirillo
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.